-
Results of a new study indicate patients who have tested positive for herpes simplex virus type 2 (HSV-2) but don't have symptoms or genital lesions still experience virus shedding during subclinical episodes.
-
The Food and Drug Administration (FDA) and the Federal Trade Commission have issued a joint call to remove products from the market that make unproven claims to treat, cure, and prevent sexually transmitted diseases (STDs).
-
Investigators have discontinued the FEM-PrEP study of oral emtricitabine and tenofovir disoproxil fumarate (Truvada, Gilead Sciences, Foster City, CA) to prevent HIV infection in women in Africa after interim results indicated the research would be unlikely to prove effectiveness in the study population.
-
Results of two case-control studies indicate that women without risk factors for venous thromboembolism (VTE) who use oral contraceptives (OCs) containing drospirenone have an increased risk for nonfatal VTE compared with those who use levonorgestrel OCs.
-
A just-published study indicates that many providers are failing to counsel women on the availability of emergency contraception (EC).
-
Add another human papillomavirus (HPV) test to the clinical arsenal. The Food and Drug Administration (FDA) has approved the Roche cobas HPV Test.
-
One woman in five develops a urinary tract infection (UTI) during her lifetime, according to the National Institute of Diabetes and Digestive and Kidney Diseases.
-
For four decades, safety-net providers such as community health centers have turned to the National Health Service Corps (NHSC) for help with maintaining a well-trained and credentialed workforce.
-
What will it take to drive down the number of chlamydia infections in young women? While routine chlamydia screening is recommended for all sexually active females age 24 years and younger, only about half (49.9%) were screened during 2008-09, according to data collected in more than 1,000 U.S. health plans.
-
In the vulvar vestibulitis clinical trial conducted at the University of Rochester between 2002 and 2007, patients with vulvar vestibulitis syndrome (localized provoked vulvodynia) were enrolled in a 12-week randomized, placebo-controlled treatment trial.
